Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 7.4%

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 836,600 shares, a decrease of 7.4% from the December 31st total of 903,100 shares. Based on an average daily volume of 420,900 shares, the short-interest ratio is presently 2.0 days.

Insiders Place Their Bets

In other Biodesix news, Director Jack W. Schuler bought 200,000 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were purchased at an average cost of $1.17 per share, for a total transaction of $234,000.00. Following the transaction, the director now directly owns 31,094,935 shares of the company's stock, valued at approximately $36,381,073.95. The trade was a 0.65 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman John Patience purchased 75,000 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was acquired at an average price of $1.38 per share, with a total value of $103,500.00. Following the purchase, the chairman now owns 2,153,298 shares in the company, valued at $2,971,551.24. This represents a 3.61 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 315,000 shares of company stock worth $393,500. Corporate insiders own 69.20% of the company's stock.

Hedge Funds Weigh In On Biodesix

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC raised its stake in Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company's stock valued at $41,000 after purchasing an additional 21,179 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix in the third quarter valued at about $262,000. Stephens Inc. AR purchased a new position in shares of Biodesix in the fourth quarter worth about $303,000. Perkins Capital Management Inc. boosted its position in Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company's stock worth $1,290,000 after acquiring an additional 310,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Biodesix by 50.7% during the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company's stock valued at $1,433,000 after acquiring an additional 270,724 shares in the last quarter. Hedge funds and other institutional investors own 20.96% of the company's stock.

Biodesix Price Performance

Biodesix stock traded down $0.01 during trading on Friday, reaching $1.03. The company had a trading volume of 246,700 shares, compared to its average volume of 419,038. The firm has a market capitalization of $149.83 million, a PE ratio of -2.64 and a beta of 1.10. The firm's 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.53. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix has a 1-year low of $0.86 and a 1-year high of $2.21.

Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The business had revenue of $18.15 million during the quarter, compared to analysts' expectations of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same quarter in the previous year, the company earned ($0.12) earnings per share. As a group, equities research analysts anticipate that Biodesix will post -0.35 earnings per share for the current fiscal year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.